Radioactive Label Patents (Class 436/504)
-
Patent number: 4508828Abstract: A method is disclosed for extraction, concentration, and bioassay measurement of the concentration of bioactive parathyroid peptides in biological or other fluids. Parathyroid peptides are extracted from the fluid by a support-antibody matrix specific to the N-terminal region. The bioassay is directed to the extracted parathyroid peptides. The volume of the medium containing the extracted parathyroid peptides and tissue, cells or tissue extracts with adenylate cyclase-coupled parathyroid hormone receptors may be chosen to be significantly less than the volume of biological or other fluid being assayed.Type: GrantFiled: March 21, 1983Date of Patent: April 2, 1985Assignee: Immuno Nuclear CorporationInventors: Arnold W. Lindall, James J. Elting
-
Patent number: 4507391Abstract: Mouse monoclonal antibody AbR.sub.24 (Dippold et al., Proc. Natl. Acad. Sci. 77:6114-6118, 1980) has a high degree of specificity for human melanoma cells when tested on viable cultured cells using the PA-MHA serological assay. The antigen detected by this antibody has been isolated from melanoma cells and shown to be G.sub.D3 ganglioside by compositional and partial structural analysis and by comparison with authentic G.sub.D3 by thin layer chromatography (TLC). AbR.sub.24 reacts with authentic G.sub.D3, but not with any other ganglioside tested. Using TLC and reactivity with AbR.sub.24, a wide range of cells and tissues was examined for the presence of G.sub.D3. A new serological assay, termed glycolipid-mediated immune adherence (GMIA), was devised for assaying the reactivity of AbR.sub.24 with gangliosides. Melanomas (cultured cells or tumor tissue) were shown to have T.sub.D3 and G.sub.M3 as major gangliosides. Other cells and tissues examined also contained G.sub.D3, but usually only in low amounts.Type: GrantFiled: April 2, 1982Date of Patent: March 26, 1985Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Clifford S. Pukel, Kenneth O. Lloyd, Luiz R. Travassos, Wolfgang G. Dippold, Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 4492760Abstract: An assay for HLA D phenotype wherein antigen-pulsed monocytes are contacted with antigen-specific T lymphocytes or T cell hybridomas and the extent of selective binding between the pulsed monocytes and the T lymphocytes or T cell hybridomas determines HLA D phenotype of the monocyte. The assay is particularly useful for quickly typing donor tissue prior to transplantation.Type: GrantFiled: April 19, 1983Date of Patent: January 8, 1985Assignee: The Wistar Institute of Anatomy and BiologyInventor: Elaine C. DeFreitas
-
Patent number: 4490472Abstract: An improved, more convenient, more sensitive test for detection of certain malignancies in human and animal subjects is disclosed. Sera from test subjects is mixed with labeled DNA in the presence of an enzyme-conjugated resin. Sera from normal and cancerous subjects react differently with the resin, permitting a diagnosis of the subject.Type: GrantFiled: June 17, 1982Date of Patent: December 25, 1984Assignee: Imreg, Inc.Inventor: A. Arthur Gottlieb
-
Patent number: 4487838Abstract: A crosslinking reagent consisting of a first functional group capable of forming a covalent derivative with a material of interest; a second functional group capable of forming an in situ bond to a neighboring material upon activation; a cleavable bond separating said first and second groups; and a radioactive marker to identify the neighboring material after cleavage of said bond, whereby in situ protein interactions can be studied.Type: GrantFiled: January 12, 1982Date of Patent: December 11, 1984Assignee: Massachusetts Institute of TechnologyInventors: Richard O. Hynes, Martin A. Schwartz
-
Patent number: 4486538Abstract: Described herein is the production of two products which are distinct species of anti-malignin antibody, and the production of three artificially produced species of cell each of which has the distinguishing characteristic of manufacturing either one or both species of anti-malignin antibody. These anti-malignin products are useful to detect the presence of cancerous or malignant tumor cells. These anti-malignin products attach preferentially to cancerous or malignant tumor cells in cell collections in vitro or in vivo and thus can be detected by any attached visible or other signal emitter. This preferential attachment to malignant tumor cells also makes these products useful for metabolic and therapeutic purposes.Type: GrantFiled: June 8, 1981Date of Patent: December 4, 1984Inventor: Samuel Bogoch
-
Patent number: 4486539Abstract: This invention relates to a diagnostic kit based on a one step hybridization procedure and method of using the kit for identifying the nucleic acids of viruses and bacteria contained in a single sample. The procedure requires two nucleic acid reagents for each microbe or group of microbes to be identified.Type: GrantFiled: October 14, 1982Date of Patent: December 4, 1984Assignee: Orioon Corporation Ltd.Inventors: Tuula M. Ranki, Soderlund Hans E.
-
Patent number: 4480040Abstract: A rapid and sensitive method for diagnosing plant viroid diseases and viruses. Plant sap is bound to a solid support and the bound sample probed with a radioactively labelled DNA that is complementary to the viroid or to the nucleic acid of the virus being diagnosed. The radioactively labelled cDNA hybridizes with that viroid or virus RNA or DNA for which it is specific. DNA-RNA and DNA-DNA hybrids are detected by autoradiographic examination of the hybridized material.Type: GrantFiled: December 3, 1981Date of Patent: October 30, 1984Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Robert A. Owens, Theodor O. Diener
-
Patent number: 4472508Abstract: An immunoassay for a specific antibody, particularly Graves' disease-specific antibody, in which interfering reactions by the reactive ends of similar antibodies are eliminated by the step of occluding the interfering reactive ends with an antibody against the interfering reactive ends.Type: GrantFiled: December 30, 1982Date of Patent: September 18, 1984Assignee: The Beth Israel Hospital AssociationInventor: Sidney H. Ingbar
-
Patent number: 4469795Abstract: A radioassay test for the rapid and sensitive determination of the concentration of monosialoglycosphingolipid G.sub.M1 ganglioside concentrations in small volumes of cerebrospinal fluid from individual patients is based on the high affinity interaction between cholera enterotoxin and G.sub.M1 ganglioside. The level of G.sub.M1 ganglioside present in the cerebrospinal fluid has been shown to be an indicator of active central nervous system pathology. In the present invention, the use of highly specific toxins eliminates cross reactivity with the other gangliosides, thereby eliminating the need to process the cerebrospinal sample prior to assay, except for centrifugation. Results of a specific application of the subject radioassay to newborn infants and older infants and children (some of the latter having active neurologic disease) indicated that the G.sub.M1 ganglioside concentration in the cerebrospinal fluid is probably a function of both central nervous system tissue ganglioside content and turnover.Type: GrantFiled: August 26, 1981Date of Patent: September 4, 1984Inventors: Edward Ginns, Joseph French
-
Patent number: 4465775Abstract: Vitamin B.sub.12 in liquid samples, such as human serum or human plasma, is assayed by a competitive binding technique using intrinsic factor and certain labelled vitamin B.sub.12 derivatives. The labelled derivatives are formed from the (d)-monocarboxylic acid isomer of vitamin B.sub.12, which isomer is free from other monocarboxylic acid isomers (and derivatives thereof) of vitamin B.sub.12, by binding to the (d)-isomer, via the carboxylic group, a compound which is itself a label (e.g. an enzyme) or which comprises a label (e.g. a fluorophore), or to which a label is attached (e.g. a histidine ester to which .sup.125 I is attached). The labelled derivatives of the (d)-monocarboxylic acid of vitamin B.sub.12, free from other isomeric monocarboxylic acids and derivatives, are novel and constitute one aspect of the invention.Type: GrantFiled: May 24, 1982Date of Patent: August 14, 1984Assignee: Technicon Instruments CorporationInventor: Thomas M. Houts
-
Patent number: 4465776Abstract: A continuous hybridoma cell line which secretes recoverable quantities of monoclonal antibodies having specificity against Vitamin B.sub.6, which antibodies are useful in a method for detecting the presence of vitamin B.sub.6 in an animal sample.Type: GrantFiled: September 27, 1982Date of Patent: August 14, 1984Assignee: Research CorporationInventors: John A. Cidlowski, Dace Viceps-Madore
-
Patent number: 4456689Abstract: An improved competitive protein binding assay comprising; incubating an analyte in the presence of labeled analyte and a protein binder suitable for competitive binding activity by the analyte and the labeled analyte to provide a mixture having free analyte, free labeled analyte, bound analyte and bound labeled analyte, substantially separating the bound analyte and the bound labeled analyte from the free analyte and free labeled analyte to form a first fraction containing substantially the bound analyte and the bound labeled analyte and a second fraction containing substantially the free analyte and the free labeled analyte by causing a predetermined level of the mixture to flow through a bed of an organo-silane coupled to silica gel, and detecting the labeled analyte of at least one of the first and second fractions to determine the concentration of the analyte by comparison to a reference.Type: GrantFiled: May 17, 1982Date of Patent: June 26, 1984Assignee: Becton Dickinson and CompanyInventors: Thomas R. Witty, Mark E. Astill
-
Patent number: 4455379Abstract: A new technique is disclosed for assaying for the presence of invasive cancer. While based on leukocyte adherence inhibition, it is improved by using relatively long lived radio-labeled leukocytes, fractionation of the leukocytes to separately treat T-cells and monocytes and by providing for human plasma or serum in the incubation medium.Type: GrantFiled: July 21, 1981Date of Patent: June 19, 1984Assignee: Mount Sinai School of Medicine of the City University of New YorkInventors: Julius G. Bekesi, James F. Holland, Peter H. Tsang
-
Patent number: 4455380Abstract: A process for determining the level of TAG in a sample of body fluid which comprises reacting the TAG in a sample of body fluid with an AG-binding lectin or L-fucose-binding lectin to form a TAG-lectin complex and measuring the amount of the TAG-lectin complex or an unreacted lectin is disclosed. The process shows low cross-reactivity with hepatic diseases and is useful for diagnosis of cancers.Type: GrantFiled: January 29, 1982Date of Patent: June 19, 1984Assignee: Otsuka Pharmaceutical Co., Ltd.Inventor: Masakazu Adachi
-
Patent number: 4454232Abstract: An improved immunoassay technique for determining the presence of estriol in human sera comprises adding preselected amounts of a non-ionic detergent and a surface active agent to the assay medium to lessen inaccuracies resulting from variable serum protein concentrations in the sample.Type: GrantFiled: June 7, 1982Date of Patent: June 12, 1984Assignee: Bio-Rad Laboratories, Inc.Inventors: Susan E. Breglio, Mark S. Hanamoto
-
Patent number: 4446237Abstract: There is disclosed a method for evaluating acellular biological fluid for viral DNA, such as DNA of the Hepatitus-B virus, whereby the acellular biological fluid is treated to immobilize in denatured form the DNAs including the suspect viral DNA on a solid support or substrate with the resulting solid substrate being contacted with a solution including radioisotropically-labeled viral denatured DNA followed by analysis of solid substrate for radioisotopically-labeled suspect viral renatured DNA.Type: GrantFiled: March 27, 1981Date of Patent: May 1, 1984Assignee: Life Technologies, Inc.Inventor: Mark S. Berninger
-
Patent number: 4433058Abstract: Diagnostic assays are provided employing a naturally occurring membrane receptor for a compound of interest and a labeled antagonist and providing for competition between the antagonist and a sample suspected of containing the compound of interest. By measuring the partition of the labeled antagonist between the receptor and the liquid aqueous assay medium, the value can be related to the amount of compound of interest in the assay medium. Specifically, a membrane from electric ray organ is used as a source of acetylcholine receptor and labeled .alpha.-bungarotoxin is used as the antagonist. The assay medium containing the sample and .alpha.-bungarotoxin is combined with the water insoluble membrane, the membrane isolated, washed, and the amount of labeled .alpha.-bungarotoxin bound to the membrane determined. By employing samples having a known amount of acetylcholine, the measured signal can be related to the amount of acetylcholine in the sample.Type: GrantFiled: February 23, 1981Date of Patent: February 21, 1984Assignee: The Regents of the University of CaliforniaInventor: James W. Deutsch
-
Patent number: 4431742Abstract: A radioreceptor assay for benzodiazepines in saliva which comprises measuring the diminution of attachment of a known quantity of radio labeled benzodiazepine to a receptor carrier in the presence of an unknown quantity of unlabeled benzodiazepine in a known amount of human saliva. Benzodiazepines are selected from the following oft-utilized drugs which are also representative types of benzodiazepine; namely, diazepam (Valium), chlordiazepoxide (Librium), nitrazepam (Benzalin), oxazepam (Serax), flurazepam (Dalmane), and clorazepate.Competitive receptors suitable for the present benzodiazepine radioreceptor assay are from fresh rat frontal cortex. Utilizable receptors are whole brain cortex, human cortex, and striatum.Type: GrantFiled: March 30, 1981Date of Patent: February 14, 1984Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Jack E. Rosenblatt
-
Patent number: 4430435Abstract: The accuracy of assays for monitoring concentrations of basic drugs in biological fluids containing .alpha..sub.1 -acid glycoproteins, such as blood (serum or plasma), is improved by the addition of certain organic phosphate compounds to minimize the "protein effect." Kits containing the elements of the invention are also disclosed.Type: GrantFiled: December 24, 1980Date of Patent: February 7, 1984Assignee: Burroughs Wellcome Co.Inventors: James V. Patzke, Burton J. Rosenberg
-
Patent number: 4426454Abstract: A diagnostic method for immune disorders comprising determining the immunoglobulin production or the DNA (deoxyribonucleic acid) synthesis of peripheral blood lymphocytes by stimulation with a new mitogen derived from either disintegrated microorganisms or culture fluid of microorganisms belonging to Staphylococcus.Type: GrantFiled: March 23, 1981Date of Patent: January 17, 1984Assignee: Fujirebio Kabushiki KaishaInventors: Tadao Aoki, Hideo Miyakoshi, Mikio Mizukoshi
-
Patent number: 4424278Abstract: A method of detecting cancer in mammals which comprises admixing with a serum sample from said mammal detectably labelled acyl carrier protein and subsequently determining the amount of B-protein-acyl carrier protein complex which is formed.Type: GrantFiled: November 16, 1981Date of Patent: January 3, 1984Assignee: Research CorporationInventors: Edsel T. Bucovaz, Walter D. Whybrew
-
Patent number: 4395486Abstract: A direct diagnosis of sickle cell anemia by a restriction endonuclease assay with an enzyme which recognizes the nucleotide base sequence CTNAG (where N is any base), such as Dde I, for the sickle cell allele (.beta..sup.s gene) through molecular hybridization. Following enzyme cleavage, the resulting DNA restriction fragments are separated by molecular weight and transferred to filter paper. A probe is utilized for hybridization that is complementary to the 5' end of the .beta. globin gene. The banding pattern of individuals with normal hemoglobin shows two bands (approximately 175 bp and 201 bp), sickle cell trait individuals exhibit an additional band (approximately 376 bp) and individuals with sickle cell anemia show the band at approximately 376 bp with a concommitant loss of the band at approximately 175 bp. Prenatal and postnatal diagnosis of sickle cell anemia is possible with the present method.Type: GrantFiled: August 19, 1981Date of Patent: July 26, 1983Assignee: Medical College of Ga. Research Inst., Inc.Inventors: Lois B. Wilson, John T. Wilson, Robert F. Geever
-
Patent number: 4375459Abstract: Novel assays are provided employing specific ells having cytoreceptors for an analyte. The assay combines the specific cells, the sample, and a tagged analyte, normally radioactively tagged. After a sufficient time, the cells are separated, conveniently by centrifugation, and either the supernatant or the cells assayed for the signal resulting from the tag.Type: GrantFiled: June 20, 1980Date of Patent: March 1, 1983Assignee: The Regents of the University of CaliforniaInventor: Stavros C. Manolagas
-
Patent number: 4366143Abstract: A method of determining the concentration of the free portion of a ligand present in a biological fluid which also contains the ligand bound to one or more natural binders involves the single step of mixing a sample of the fluid with a labelled derivative of the ligand and a specific binder for the ligand, incubating the mixture, and determining the proportion of the labelled derivative of the ligand bound to the specific binder. The labelled derivative of the ligand is chosen to bind strongly to the added specific binder, but to bind not at all, or much more weakly than does the ligand, to the natural binders in the biological fluid. A small amount of the labelled derivative can be used, and the binding equilibrium of the ligand is not appreciably perturbed. Ligands include thyroxine, tri-iodothyroxine and cortisol.Type: GrantFiled: September 22, 1980Date of Patent: December 28, 1982Assignee: Amersham International Public Limited CompanyInventors: John E. Midgley, Terence A. Wilkins